Latest Paladin Labs Inc. Stories
SYDNEY and BEDMINSTER, N.J., Oct. 9, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Paladin Labs Inc. ("Paladin") (TSX:PLB) for the Canadian commercialisation rights to MOXDUO(®), a patented, immediate release formulation of morphine and oxycodone. Paladin is a leading Canadian specialty pharmaceutical company headquartered in Montreal, Canada, and is listed on the Toronto Stock Exchange. Paladin has...
MISSISSAUGA, ON, Aug. 1, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the second quarter ended June 30, 2012. Second Quarter and Recent Corporate Developments: -- The Company received notice of a positive opinion from the...
MISSISSAUGA, ON and MONTREAL, May 28, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, and Paladin Labs Inc. (TSX: PLB), a leading specialty pharmaceutical company, announced today that they have entered into a license and supply agreement granting Paladin exclusive Canadian rights to market and...
- Companies Establish Licensing and Distribution Agreements for Labopharm's INTELLITAB(TM)-Based Oxycodone-Acetaminophen and Twice-Daily Tramadol Acetaminophen - LAVAL, QC and MONTREAL, Oct. 14 /PRNewswire/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) and Paladin Labs Inc. (TSX:PLB) today announced they have expanded their commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions....
TSX Venture: QPT EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (TSX:PLB) ("Paladin"). The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumor antigens that are presented in a...
LAKE FOREST, Ill., Sept. 24 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO) "The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche...
MONTREAL, QUEBEC--(Marketwire - July 2, 2008) - Paladin Labs Inc. (TSX:PLB) and Procter & Gamble (P&G) Pharmaceuticals Canada, Inc., today announced that the companies have entered into a Canadian Co- Promotion Agreement for SEASONALE(TM) - the first and only extended- cycle oral contraceptive available in Canada. With SEASONALE(TM), Canadian women have an oral contraceptive option that will allow them to have just four periods per year. SEASONALE(TM) (levonorgestrel and ethinyl estradiol...
